Mechanochemical Ablation Versus Ultrasound-Guided Foam Sclerotherapy of the Great Saphenous Vein
Mechanochemical Ablation Versus Ultrasound-Guided Foam Sclerotherapy of the Great Saphenous Vein: Randomized Clinical Trial
This study compares two minimally invasive treatments for varicose veins in the legs, specifically the great saphenous vein.
Varicose veins can cause symptoms such as leg pain, swelling, and skin changes. One commonly used treatment is foam sclerotherapy, where a special foam is injected into the vein to close it. This method is simple and allows patients to return quickly to their daily activities, but sometimes the vein can reopen, requiring additional treatments.
Another option is mechanochemical ablation, which combines a small device with a medication to close the vein. This method also allows for quick recovery and may have a lower chance of the vein reopening.
In this study, 50 patients with varicose veins will be randomly assigned to receive one of these two treatments. Doctors will follow patients over time to evaluate:
How well the treated vein stays closed Improvement in quality of life Pain during the procedure Possible complications All procedures are performed with local anesthesia, and additional small varicose veins are treated at the same time.
調査の概要
状態
詳細な説明
Introduction:
Ultrasound-guided foam sclerotherapy is a widely used method for the treatment of lower limb varicose veins. Its main advantages include applicability in patients at high surgical risk and immediate or early return to daily activities. However, it requires a higher number of reinterventions compared to other techniques due to increased rates of venous recanalization, particularly in larger-caliber veins. In contrast, mechanochemical ablation shares these advantages and is associated with lower recanalization rates.
Objective:
To compare ultrasound-guided foam sclerotherapy of the great saphenous vein (GSV) with mechanochemical ablation using the Flebogrif® catheter in the treatment of chronic venous insufficiency (CVI) associated with GSV disease. The primary endpoints will be quality of life assessment and GSV occlusion rate, as determined by lower limb venous color Doppler ultrasonography over the proposed follow-up period. Secondary endpoints include the incidence of treatment-related complications and pain level during the procedure.
Patients and Methods:
A total of 50 patients with primary varicose veins will be selected. Inclusion criteria include lower limb pain, edema, or skin changes such as hyperpigmentation, eczema, and lipodermatosclerosis (CEAP classification C2-C4, EpAsPr), as well as GSV insufficiency with a diameter between 6 and 12 mm measured at the mid-thigh using color Doppler ultrasonography. Clinical evaluations and ultrasound examinations will be conducted at the venous disease outpatient clinic, and procedures will be performed in the minor surgery operating room of the University of São Paulo Hospital.
This will be a prospective randomized study, with patients allocated into two groups according to the treatment technique.
Group 1: Percutaneous puncture and ultrasound-guided injection of sclerosant foam through a short 18G catheter.
Group 2: Use of the Flebogrif® catheter, positioned under ultrasound guidance 2 cm from the saphenofemoral junction, followed by catheter withdrawal combined with sclerosant foam injection.
In both groups, 20 mL of 0.9% saline solution will be infused prior to polidocanol administration. The GSV puncture site will depend on the extent of insufficiency (segmental or total), being performed at the knee or medial malleolar region, respectively, after local anesthesia with 2% lidocaine without vasoconstrictor and without infiltration along the venous course.
For knee-level puncture, a tourniquet will be applied distal to the access site and maintained for 5 minutes after foam injection to prevent dispersion into healthy venous segments.
In all patients, varicose tributaries will be treated immediately after the GSV procedure using 1% polidocanol sclerotherapy.
Expected Results:
Mechanochemical ablation is expected to demonstrate a higher target vein occlusion rate with lower recanalization rates, without increased procedural pain and with at least a comparable complication rate to ultrasound-guided foam sclerotherapy. This study aims to contribute to the refinement of treatment strategies, seeking greater efficacy with monotherapy.
研究の種類
入学 (推定)
段階
- フェーズ 4
連絡先と場所
研究連絡先
- 名前:Antonio Zerati, PhD
- 電話番号:+5511996354925
- メール:a.zerati@fm.usp.br
研究場所
-
-
São Paulo
-
São Paulo、São Paulo、ブラジル
- 募集
- Hospital da Clínicas da FMUSP
-
コンタクト:
- Victor Minari Campos, MD
- 電話番号:+5511997596010
- メール:victorminaricampos@gmail.com
-
主任研究者:
- Antonio Zerati, PhD
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- CEAP Classification C2, 3 or 4
- Insufficient great saphenous vein measuring 6-12 mm in the mid-thigh on Doppler ultrasound.
Exclusion Criteria:
- Allergy to sclerosing substances
- Deep venous thrombosis, stroke, or pulmonary embolism
- Local or generalized infection at the sclerotherapy site
- Prolonged immobilization
- Asymptomatic patent foramen ovale
- Pregnancy Occlusive peripheral arterial disease
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Great saphenous vein insufficiency (1)
25 limbs with great saphenous vein insufficiency
|
Mechanical-chemical ablation is a technique for treating varicose veins that combines mechanical damage to the venous endothelium with chemical damage using polidocanol foam.
Polidocanol foam is a drug infused into varicose veins, causing chemical damage to the endothelium.
|
|
実験的:Great saphenous vein insufficiency (2)
25 limbs with great saphenous vein insufficiency
|
Mechanical-chemical ablation is a technique for treating varicose veins that combines mechanical damage to the venous endothelium with chemical damage using polidocanol foam.
Polidocanol foam is a drug infused into varicose veins, causing chemical damage to the endothelium.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Quality Of Life Score: Brazilian Version Adapted from the Aberdeen Varicose Veins Questionnaire
時間枠:From enrollment to the end of treatment at 365 days after procedure
|
Brazilian Version Adapted from the Aberdeen Varicose Veins Questionnaire will be used.
Score from 0 to 100, where 0 is the best and 100 is the worst quality of life related to varicose veins.
|
From enrollment to the end of treatment at 365 days after procedure
|
|
Disease Severity Score: Venous Clinical Severity Score (VCSS)
時間枠:From enrollment to the end of treatment at 365 days after procedure
|
Venous Clinical Severity Score (VCSS) will be used.
Score from 0 to 30, where 0 means asymptomatic patient and 30 means more symptomatic patient as possible.
|
From enrollment to the end of treatment at 365 days after procedure
|
|
Ultrasound Assessment: Classification of the Second European Consensus Meeting on Foam Sclerotherapy Held in Tegernsee, Germany in 2006
時間枠:From enrollment to the end of treatment at 365 days after procedure
|
Classification of the Second European Consensus Meeting on Foam Sclerotherapy Held in Tegernsee, Germany in 2006, will be used.
Classification where 0 means reflux greater than 1 second, 1 means reflux less than 1 second, and 2 means no reflux.
|
From enrollment to the end of treatment at 365 days after procedure
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Treatment complications
時間枠:One to 365 after procedure
|
Deep vein thrombosis, thrombophlebitis, visual disturbances, skin irritation and skin hyperpigmentation.
|
One to 365 after procedure
|
|
Pain Level During Procedure: Visual Analog Pain Scale
時間枠:Pain level during the procedure
|
Visual Analog Pain Scale will be used.
Scale where 0 means no pain and 10 means maximum pain during procedure.
|
Pain level during the procedure
|
協力者と研究者
スポンサー
出版物と役立つリンク
一般刊行物
- Nicolaides AN, Allegra C, Bergan J, Bradbury A, Cairols M, Carpentier P, Comerota A, Delis C, Eklof B, Fassiadis N, Georgiou N, Geroulakos G, Hoffmann U, Jantet G, Jawien A, Kakkos S, Kalodiki E, Labropoulos N, Neglen P, Pappas P, Partsch H, Perrin M, Rabe E, Ramelet AA, Vayssaira M, Ioannidou E, Taft A. Management of chronic venous disorders of the lower limbs: guidelines according to scientific evidence. Int Angiol. 2008 Feb;27(1):1-59. No abstract available.
- Epstein D, Onida S, Bootun R, Ortega-Ortega M, Davies AH. Cost-Effectiveness of Current and Emerging Treatments of Varicose Veins. Value Health. 2018 Aug;21(8):911-920. doi: 10.1016/j.jval.2018.01.012. Epub 2018 Mar 15.
- Petrone A, Peluso A, Ammollo RP, Turchino D, Del Guercio L, Andreucci M, Serra R, Bracale UM. Selective crossectomy combined with mechanochemical ablation in the treatment of great saphenous vein insufficiency: Early results of a single center experience. Phlebology. 2022 Aug;37(7):522-528. doi: 10.1177/02683555221092194. Epub 2022 Apr 25.
- Whing J, Nandhra S, Nesbitt C, Stansby G. Interventions for great saphenous vein incompetence. Cochrane Database Syst Rev. 2021 Aug 11;8(8):CD005624. doi: 10.1002/14651858.CD005624.pub4.
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 83198024.0.0000.0068
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。